Dr. Lowentritt on choosing the right therapies for patients with mCSPC

“I think we're at a point where we have this luxury of many options, which is great, but we still need to continue to be really thoughtful in how we choose those options,” says Benjamin Lowentritt, MD, FACS.

In this video, Benjamin Lowentritt, MD, FACS, discusses the takeaways of the study, “Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Lowentritt is the director of minimally invasive surgery and robotics and the director of the Prostate Cancer Care Program at Chesapeake Urology in Baltimore, Maryland.